valacyclovir and Nervous-System-Diseases

valacyclovir has been researched along with Nervous-System-Diseases* in 3 studies

Reviews

1 review(s) available for valacyclovir and Nervous-System-Diseases

ArticleYear
Cytomegalovirus infection during pregnancy: stateĀ of the science.
    American journal of obstetrics and gynecology, 2020, Volume: 223, Issue:3

    Cytomegalovirus is the most common congenital infection, affecting 0.5-2% of all live births and the main nongenetic cause of congenital sensorineural hearing loss and neurological damage. Congenital cytomegalovirus can follow maternal primary infection or nonprimary infection. Sensorineurological morbidity is confined to the first trimester with up to 40-50% of infected neonates developing sequelae after first-trimester primary infection. Serological testing before 14 weeks is critical to identify primary infection within 3 months around conception but is not informative in women already immune before pregnancy. In Europe and the United States, primary infection in the first trimester are mainly seen in young parous women with a previous child younger than 3 years. Congenital cytomegalovirus should be evoked on prenatal ultrasound when the fetus is small for gestation and shows echogenic bowel, effusions, or any cerebral anomaly. Although the sensitivity of routine ultrasound in predicting neonatal symptoms is around 25%, serial targeted ultrasound and magnetic resonance imaging of known infected fetuses show greater than 95% sensitivity for brain anomalies. Fetal diagnosis is done by amniocentesis from 17 weeks. Prevention consists of both parents avoiding contact with body fluids from infected individuals, especially toddlers, from before conception until 14 weeks. Candidate vaccines failed to provide more than 75% protection for >2 years in preventing cytomegalovirus infection. Medical therapies such as cytomegalovirus hyperimmune globulins aim to reduce the risk of vertical transmission but 2 randomized controlled trials have not found any benefit. Valaciclovir given from the diagnosis of primary infection up to amniocentesis decreased vertical transmission rates from 29.8% to 11.1% in the treatment group in a randomized controlled trial of 90 pregnant women. In a phase II open-label trial, oral valaciclovir (8 g/d) given to pregnant women with a mildly symptomatic fetus was associated with a higher chance of delivering an asymptomatic neonate (82%), compared with an untreated historical cohort (43%). Valganciclovir given to symptomatic neonates is likely to improve hearing and neurological symptoms, the extent of which and the duration of treatment are still debated. In conclusion, congenital cytomegalovirus infection is a public health challenge. In view of recent knowledge on diagnosis and pre- and postnatal management, health care providers shoul

    Topics: Cytomegalovirus Infections; Female; Fetal Diseases; Hearing Loss, Sensorineural; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Magnetic Resonance Imaging; Nervous System Diseases; Preconception Care; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Prenatal Diagnosis; Serologic Tests; Ultrasonography, Prenatal; Valacyclovir

2020

Other Studies

2 other study(ies) available for valacyclovir and Nervous-System-Diseases

ArticleYear
Possible valacyclovir-related neurotoxicity and aseptic meningitis.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:12

    To report a case of neurotoxicity and aseptic meningitis in a patient receiving valacyclovir.. An 86-year-old white man had started valacyclovir 1 g 3 times a day for a herpetic rash along the left side of his face. He subsequently presented with balance difficulties, constant frontal headaches, and a seizure 1 day prior to admission. Cerebral spinal fluid (CSF) analysis revealed 162 white cells/mm(3), 1 red blood cell/mm(3), glucose 56 mg/dL, and protein 144 mg/dL, with a negative Gram stain. Further laboratory examination failed to demonstrate other causes for the patient's clinical picture. After discontinuation of valacyclovir and supportive care, the patient symptomatically improved.. As of the third week of September 2003, only 1 other case of valacyclovir-related aseptic meningitis was published describing a patient with characteristics similar to those of our patient. Our patient's neurologic symptoms may have been due to acyclovir toxicity, but acyclovir-toxic patients present with normal CSF findings. Several drug classes, including nonsteroidal antiinflammatory drugs, antibiotics, and intravenous immunoglobulins, can induce aseptic meningitis. Other reasons for the patient's symptoms or causes of meningitis were excluded, although viral meningitis remains a possibility. Valacyclovir-induced aseptic meningitis was considered to be possible according to the Naranjo probability scale.. Healthcare providers should be aware of valacyclovir as a possible cause of drug-induced aseptic meningitis.

    Topics: Acyclovir; Aged; Aged, 80 and over; Humans; Male; Meningitis, Aseptic; Nervous System Diseases; Valacyclovir; Valine

2003
Neurotoxicity caused by valacyclovir in a patient on hemodialysis.
    Therapeutic drug monitoring, 1998, Volume: 20, Issue:4

    The authors report toxicity caused by valacyclovir in a patient on hemodialysis. After initial recuperation resulting from treatment with hemodialysis, the patient experienced a relapse of neurologic symptoms, again necessitating hemodialysis. Although acyclovir and its analogues are generally safe drugs, they should be used with caution in patients with end-stage renal disease. Therapeutic drug monitoring may be indicated.

    Topics: Acyclovir; Antiviral Agents; Humans; Male; Middle Aged; Nervous System Diseases; Renal Dialysis; Valacyclovir; Valine

1998